Advanced Medical Solutions Group (AMS)

Sector:

Health Care

Index:

FTSE AIM 50

 210.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 258.00p
  • 52 Week Low: 177.20p
  • Currency: UK Pounds
  • Shares Issued: 217.41m
  • Volume: 0
  • Market Cap: £457.65m
  • RiskGrade: 156

Advanced Medical Solutions shares manage gains on 2018 growth

By Josh White

Date: Wednesday 13 Mar 2019

LONDON (ShareCast) - (Sharecast News) - Surgical and advanced wound care specialist company Advanced Medical Solutions Group reported a 6% rise in its revenues in its preliminary results on Wednesday, to £102.6m, and by 7% at constant currency.
The AIM-traded firm said branded revenues were ahead 12% to £62.1m in the year ended 31 December, and by 13% at constant currency.

Original equipment manufacturer (OEM) revenues slipped 3% to £40.5m, and by 2% at constant currency.

Advanced Medical Solutions said its adjusted operating margin was up 180 basis points to 28.0%, while its adjusted profit before tax improved 14% to £28.9m.

It reported continued strong performance from its 'LiquiBand' topical tissue adhesives, with sales up 22% to £31.7m, and by 24% at constant currency.

US revenues were 26% higher at £23.0 million, and by 30% at constant currency, while its market share by volume advanced by 2% during the year.

There was said to have been "strong growth" in its internal adhesives operation, following the relaunch of 'LiquiBand Fix 8' laparoscopic in the second quarter and the soft launch of the open device in the fourth quarter.

Sales increased 21% to £2.1m at both actual and constant exchange rates.

Advanced Medical Solutions said sales of collagens and other biosurgical devices increased by 8% to £8.6m, and by 6% at constant currency, while sales of sutures were impacted by regulatory challenges, rising 1% at reported and constant currency to £13.3m.

Antimicrobial dressings were 1% higher at £19.6m, and 2% at constant currency.

Post-period end, in January, the company announced the acquisition of Sealantis for $25m (approximately £19m) in cash, with royalties due on product sales until 2027.

It said the acquisition would give it the technology platform and products to enter the $1bn internal sealants market, with the first product expected in the the European market in the first half of 2021, and multiple potential additional sealant products.

The board also highlighted the appointment of Eddie Johnson as its chief financial officer and a board director on 1 January, following the retirement of Mary Tavener following 19 years of service.

Advanced Medical Solutions proposed a final dividend of 0.90p per share, making a total dividend for the year of 1.32p per share, which was up 20% year-on-year.

"2018 was AMS's 17th consecutive year of growth with strong financial and strategic progress across the group," said chief executive officer Chris Meredith.

"Our solid revenue growth was driven by sales in our branded division which included LiquiBand topical tissue adhesives further increasing market share a further 2%, and the growth of our internal adhesives and biosurgical devices."

Meredith said the company had further reaffirmed its commitment to innovation through the acquisition of Sealantis, which now opened up the large internal sealants market for the group.

"We are well positioned to take advantage of market opportunities across our product portfolio, and we continue to actively review merger and acquisition opportunities."

As at 1454 GMT, shares in Advanced Medical Solutions Group were ahead 0.49% at 307p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AMS Market Data

Currency UK Pounds
Share Price 210.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 258.00p
52 Week Low 177.20p
Volume 0
Shares Issued 217.41m
Market Cap £457.65m
RiskGrade 156

AMS Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
71.56% below the market average71.56% below the market average71.56% below the market average71.56% below the market average71.56% below the market average
25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average25.00% above the sector average
Price Trend
31.67% below the market average31.67% below the market average31.67% below the market average31.67% below the market average31.67% below the market average
22.22% above the sector average22.22% above the sector average22.22% above the sector average22.22% above the sector average22.22% above the sector average
Income
86.89% below the market average86.89% below the market average86.89% below the market average86.89% below the market average86.89% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
37.71% below the market average37.71% below the market average37.71% below the market average37.71% below the market average37.71% below the market average
72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average72.22% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 2
Sell 1
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AMS Dividends

  Latest Previous
  Final Interim
Ex-Div 30-May-24 28-Sep-23
Paid 21-Jun-24 27-Oct-23
Amount 1.66p 0.70p

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

AMS Key Personnel

CEO A Christopher (Chris) Meredith
CFO Eddie Johnson
Chair Liz Shanahan

Top of Page